April 16, 2024

Genitourinary Drugs Market Size To Rake USD 32.27 Bn By 2032

The genitourinary drugs market size is poised to grow by USD 32.27 billion by 2032 from USD 29.24 billion in 2023, exhibiting a CAGR of 1.1% during the forecast period 2023-2032.

Genitourinary Drugs Market Size 2023 To 2032

Key Takeaways

  • North America contributed more than 49% of revenue share in 2022.
  • Asia-Pacific is estimated to witness the fastest CAGR between 2023 and 2032.
  • By indication, the prostate cancer segment held the largest market share of 28% in 2022.
  • By indication, the cervical cancer segment is anticipated to grow at a remarkable CAGR of 2.5% between 2023 and 2032.
  • By product, the hormonal therapy segment generated over 38% of revenue share in 2022.
  • By product, the gynecological segment is expected to expand at the fastest CAGR over the projected period.

Precedence Research has conducted a comprehensive market study that provides valuable insights into the performance of the market during the forecast period. The study identifies significant trends that are shaping the growth of the Genitourinary drugs market. In this recently published report, essential dynamics such as drivers, restraints, and opportunities are highlighted for both established market players and emerging participants involved in production and supply.

To begin with, the Genitourinary drugs Market report features an executive summary that offers a concise overview of the marketplace. It outlines the key players and industry categories expected to have an impact on the market in the coming years. The executive summary provides an unbiased summary of the market.

Get a Sample Reporthttps://www.precedenceresearch.com/sample/3644

Genitourinary Drugs Market Scope

Report Coverage Details
Market Size in 2023 USD 29.24 Billion
Market Size by 2032 USD 32.27 Billion
Growth Rate from 2023 to 2032 CAGR of 1.1%
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Indication and By Product
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Read More: Colorectal Cancer Therapeutics Market Size To Gain USD 18.25 Bn by 2032

The empirical study on the global Genitourinary drugs market primarily focuses on the drivers in subsequent sections. It demonstrates how changing demographics are projected to influence the supply and demand dynamics in the Genitourinary drugs Market. Our market report for the Genitourinary drugs market also delves into the significant rules and regulations that are likely to impact the future growth of this sector. Moreover, in order to comprehend the underlying demand factors, industry experts have provided insights into its fundamental origins.

Recent Developments

  • In April 2023, GSK plc reported encouraging results from the EAGLE-2 and EAGLE-3 clinical trials for gepotidacin. The positive outcome in Phase III trials positions gepotidacin as a potential breakthrough, being the first orally administered antibiotic in its class for treating uncomplicated urinary tract infections (uUTI) in female adolescents and adults.
  • In March 2023, Pfizer Inc. disclosed its definitive merger agreement with Seagen Inc., a biotechnology firm known for its innovation in cancer medicines and expertise in antibody-drug conjugate (ADC) technology. This strategic collaboration marks a significant development in Pfizer’s pursuit of advancements in cancer treatment and underscores Seagen’s valued position in the field.

Genitourinary Drugs Market Players

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Bayer AG
  • Sanofi S.A.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Takeda Pharmaceutical Company Limited 

Data Sources and Methodology

To gather comprehensive insights on the Global Genitourinary drugs Market, we relied on a range of data sources and followed a well-defined methodology. Our approach involved interactions with industry experts and key stakeholders across the market’s value chain, including management organizations, processing organizations, and analytics service providers.

We followed a rigorous data analysis process to ensure the quality and credibility of our research. The gathered information was carefully evaluated, and relevant quantitative data was subjected to statistical analysis. By employing robust analytical techniques, we were able to derive meaningful insights and present a comprehensive overview of the Global Genitourinary drugs Market.

The most resonating, simple, genuine, and important causes because of which you must decide to buy the Genitourinary drugs market report exclusively from precedence research

  • The research report has been meticulously crafted to provide comprehensive knowledge on essential marketing strategies and a holistic understanding of crucial marketing plans spanning the forecasted period from 2023 to 2032.

Key Features of the Report:

  • Comprehensive Coverage: The report extensively encompasses a detailed explanation of highly effective analytical marketing methods applicable to companies across all industry sectors.
  • Decision-Making Enhancement: It outlines a concise overview of the decision-making process while highlighting key techniques to enhance it, ensuring favorable business outcomes in the future.
  • Articulated R&D Approach: The report presents a well-defined approach to conducting research and development (R&D) activities, enabling accurate data acquisition on current and future marketing conditions.

Market Segmentation:

By Indication

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Haematuria
  • Benign Prostatic Hyperplasia

By Product

  • Urologicals
  • Hormonal Therapy
  • Gynecological
  • Anti-infectives
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Reasons to Consider Purchasing the Report:

  • Enhance your market research capabilities by accessing this comprehensive and precise report on the global Genitourinary drugs market.
  • Gain a thorough understanding of the overall market landscape and be prepared to overcome challenges while ensuring robust growth.
  • Benefit from in-depth research and analysis of the latest trends shaping the global Genitourinary drugs market.
  • Obtain detailed insights into evolving market trends, current and future technologies, and strategic approaches employed by key players in the global Genitourinary drugs market.
  • Receive valuable recommendations and guidance for both new entrants and established players seeking further market expansion.
  • Discover not only the cutting-edge technological advancements in the global Genitourinary drugs market but also the strategic plans of industry leaders.

Table of Content

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genitourinary Drugs Market 

5.1. COVID-19 Landscape: Genitourinary Drugs Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genitourinary Drugs Market, By Indication

8.1. Genitourinary Drugs Market Revenue and Volume, by Indication, 2023-2032

8.1.1. Prostate Cancer

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Ovarian Cancer

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Bladder Cancer

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Cervical Cancer

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Renal Cancer

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Erectile Dysfunction

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

8.1.7. Urinary Tract Infections

8.1.7.1. Market Revenue and Volume Forecast (2020-2032)

8.1.8. Urinary Incontinence & Overactive Bladder

8.1.8.1. Market Revenue and Volume Forecast (2020-2032)

8.1.9. Sexually Transmitted Diseases

8.1.9.1. Market Revenue and Volume Forecast (2020-2032)

8.1.10. Interstitial Cystitis

8.1.10.1. Market Revenue and Volume Forecast (2020-2032)

8.1.11. Haematuria

8.1.11.1. Market Revenue and Volume Forecast (2020-2032)

8.1.12. Benign Prostatic Hyperplasia

8.1.12.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Genitourinary Drugs Market, By Product

9.1. Genitourinary Drugs Market Revenue and Volume, by Product, 2023-2032

9.1.1. Urologicals

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Hormonal Therapy

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Gynecological

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

9.1.4. Anti-infectives

9.1.4.1. Market Revenue and Volume Forecast (2020-2032)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Genitourinary Drugs Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.1.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.2.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.3.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.4.6.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.3.2. Market Revenue and Volume Forecast, by Product (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Indication (2020-2032)

10.5.4.2. Market Revenue and Volume Forecast, by Product (2020-2032)

Chapter 11. Company Profiles

11.1. GlaxoSmithKline

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. AstraZeneca

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. CytoSorbents Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cardinal Health

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Asahi Kasei

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. ConvaTec

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. CHIESI Farmaceutici

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Smith & Nephew

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

 

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

Precedence Statistics – Empowering Your Data Insights

 

Contact Us

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Leave a Reply

Your email address will not be published. Required fields are marked *